Liver and diabetes. A vicious circle

DOI: 10.1111/j.1872-034x.2012.01031.x
Hepatology Research, 2013, 43, 51-64.

#	Paper	IF	Citations
150	Moderate physical activity from childhood contributes to metabolic health and reduces hepatic fat accumulation in adult rats. **2013**, 12, 29		7
149	Pharmacological agents for nonalcoholic steatohepatitis. **2013**, 7 Suppl 2, 833-41		2
148	Uncovering the beginning of diabetes: the cellular redox status and oxidative stress as starting players in hyperglycemic damage. **2013**, 376, 103-10		30
147	Remodeling of liver phospholipidomic profile in streptozotocin-induced diabetic rats. **2013**, 538, 95-102		12
146	Long-lasting improvements in liver fat and metabolism despite body weight regain after dietary weight loss. **2013**, 36, 3786-92		38
145	To binge or not to binge: binge drinking disrupts glucose homeostasis by impairing hypothalamic but not liver insulin signaling. **2013**, 57, 2535-8		4
144	Interaction of type 2 diabetes and nonalcoholic fatty liver disease. **2013**, 7, 405-7		8
143	Nonalcoholic Fatty liver: a possible new target for type 2 diabetes prevention and treatment. *International Journal of Molecular Sciences*, **2013**, 14, 22933-66	6.3	72
142	Recurrent Hepatitis in Two Iranian Children: A Novel (Q166R) Mutation in EIF2AK3 Leading to Wolcott-Rallison Syndrome. **2013**, 13, e10124		4
141	The association between nonalcoholic fatty pancreas disease and diabetes. *PLoS ONE*, **2013**, 8, e62561	3.7	95
140	Gastrointestinal complications of diabetes mellitus. **2013**, 4, 51-63		103
139	Hepatic function and the cardiometabolic syndrome. *Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy*, **2013**, 6, 379-88	3.4	20
138	Oxidant status and lipid composition of erythrocyte membranes in patients with type 2 diabetes, chronic liver damage, and a combination of both pathologies. **2013**, 2013, 657387		7
137	Reduced oxidative stress contributes to the lipid lowering effects of isoquercitrin in free fatty acids induced hepatocytes. **2014**, 2014, 313602		37
136	Subclinical abnormal glucose tolerance is a predictor of death in liver cirrhosis. *World Journal of Gastroenterology*, **2014**, 20, 7011-8	5.6	20
135	Nonalcoholic fatty liver disease and aging: epidemiology to management. *World Journal of Gastroenterology*, **2014**, 20, 14185-204	5.6	158
134	Serum hepassocin concentrations in diabetic patients with or without nonalcoholic fatty liver disease. **2014**, 4, 255-261		6

133	Non-alcoholic fatty liver disease: diagnosis and investigation. **2014**, 32, 586-96		8
132	Role of mitochondria in nonalcoholic fatty liver disease. *International Journal of Molecular Sciences*, **2014**, 15, 8713-42	6.3	183
131	Association between interferon use and reduced metabolic and vascular complications among patients with hepatitis C. **2014**, 8, 973-83		
130	Multiple pathways are involved in palmitic acid-induced toxicity. **2014**, 67, 26-34		46
129	Simple steatosis is a more relevant source of serum inflammatory markers than omental adipose tissue. **2014**, 38, 46-54		16
128	Hepatic steatosis and steatohepatitis: Are they really two distinct entities?. **2014**, 13, 151-158		14
127	Non-alcoholic fatty liver disease: a diabetologistB perspective. **2014**, 45, 344-53		41
126	Personalized metabolic profile estimations using oral glucose tolerance tests. **2014**, 116, 25-32		3
125	Pharmacokinetics in patients with chronic liver disease and hepatic safety of incretin-based therapies for the management of type´2 diabetes mellitus. **2014**, 53, 773-85		31
124	Pharmacokinetic and toxicological considerations for the treatment of diabetes in patients with liver disease. **2014**, 10, 839-57		35
123	Cardiovascular risk, lipidemic phenotype and steatosis. A comparative analysis of cirrhotic and non-cirrhotic liver disease due to varying etiology. **2014**, 232, 99-109		97
122	Identification of reciprocal causality between non-alcoholic fatty liver disease and metabolic syndrome by a simplified Bayesian network in a Chinese population. **2015**, 5, e008204		38
121	Exercise training improves liver steatosis in mice. **2015**, 12, 29		19
120	Hepatic PTEN deficiency improves muscle insulin sensitivity and decreases adiposity in mice. **2015**, 62, 421-9		37
119	Nonalcoholic fatty liver disease: a precursor of the metabolic syndrome. **2015**, 47, 181-90		430
118	Diagnosis and management of cardiovascular risk in nonalcoholic fatty liver disease. **2015**, 9, 629-50		57
117	FT3/FT4 ratio predicts non-alcoholic fatty liver disease independent of metabolic parameters in patients with euthyroidism and hypothyroidism. **2016**, 71, 221-5		22
116	Type 2 Diabetes in Non-Alcoholic Fatty Liver Disease and Hepatitis C Virus Infection--Liver: The "Musketeer" in the Spotlight. *International Journal of Molecular Sciences*, **2016**, 17, 355	6.3	30

115	Fatty liver is associated with an increased risk of diabetes and cardiovascular disease - Evidence from three different disease models: NAFLD, HCV and HIV. *World Journal of Gastroenterology*, **2016**, 22, 9674-9693	5.6	69
114	Abnormalities in the Metabolism of Fatty Acids and Triacylglycerols in the Liver of the Goto-Kakizaki Rat: A Model for Non-Obese Type 2 Diabetes. **2016**, 51, 955-71		9
113	Short-Term Hypocaloric High-Fiber and High-Protein Diet Improves Hepatic Steatosis Assessed by Controlled Attenuation Parameter. **2016**, 7, e176		23
112	Prevalence of abnormal serum liver enzymes in patients with type 2 diabetes mellitus: a cross-sectional study from China. **2016**, 128, 770-776		12
111	Nonalcoholic steatohepatitis and diabetes. **2016**, 63, 377-379		3
110	Peretinoin as an adjuvant therapy for hepatocellular carcinoma. **2016**, 10, 1201-1210		3
109	Nonalcoholic steatohepatitis and diabetes. **2016**, 63, 377-9		3
108	Pathogenesis of nonalcoholic steatohepatitis. **2016**, 73, 1969-87		111
107	The Role of Nuclear Receptors in the Pathophysiology, Natural Course, and Drug Treatment of NAFLD in Humans. **2016**, 33, 291-319		54
106	Nonalcoholic fatty liver disease and hepatocellular carcinoma. **2016**, 65, 1151-60		98
105	Weight Change-Adjusted Effects of Gastric Bypass Surgery on Glucose Metabolism: 2- and 10-Year Results From the Swedish Obese Subjects (SOS) Study. **2016**, 39, 625-31		40
104	A Synthetic-Biology-Inspired Therapeutic Strategy for Targeting and Treating Hepatogenous Diabetes. **2017**, 25, 443-455		30
103	Pharmacological management of nonalcoholic fatty liver disease in type 2 diabetes. **2017**, 10, 535-547		13
102	Metabolic concerns in aging HIV-infected persons: from serum lipid phenotype to fatty liver. **2017**, 31 Suppl 2, S147-S156		23
101	NAFLD as a Sexual Dimorphic Disease: Role of Gender and Reproductive Status in the Development and Progression of Nonalcoholic Fatty Liver Disease and Inherent Cardiovascular Risk. **2017**, 34, 1291-1326		232
100	Clinical characteristics of patients with diabetes mellitus and fatty liver diagnosed by liver/spleen Hounsfield units on CT scan. **2017**, 45, 1208-1220		6
99	Adipocyte-Specific Deficiency of NADPH Oxidase 4 Delays the Onset of Insulin Resistance and Attenuates Adipose Tissue Inflammation in Obesity. **2017**, 37, 466-475		62
98	Glucagon-like peptide-1 effects lipotoxic oxidative stress by regulating the expression of microRNAs. **2017**, 482, 1462-1468		6

97	Using proteomics to discover novel biomarkers for fatty liver development and response to CB1R antagonist treatment in an obese mouse model. **2017**, 17, 1600292		3
96	Esteatosis hepática: diagnóstico y seguimiento. **2017**, 24, 378-389		0
95	Factors affecting mortality and resource use for hospitalized patients with cirrhosis: A population-based study. **2017**, 96, e7782		7
94	Nonalcoholic fatty liver disease: Evolving paradigms. *World Journal of Gastroenterology*, **2017**, 23, 6571-6592	3.0	92
93	Clinical course of nonalcoholic fatty liver disease: an assessment of severity, progression, and outcomes. **2017**, 9, 679-688		23
92	Prognostic impact of diabetes mellitus on hepatocellular carcinoma: Special emphasis from the BCLC perspective. *PLoS ONE*, **2017**, 12, e0174333	3.7	9
91	Non-alcoholic Fatty Liver Disease: A Clinical Update. **2017**, 5, 384-393		69
90	Modulation of diabetes-related liver injury by the HMGB1/TLR4 inflammatory pathway. **2018**, 74, 345-358		13
89	Nonalcoholic fatty liver disease as a sentinel marker for the development of diabetes mellitus in non-obese subjects. **2018**, 50, 370-377		29
88	Nonalcoholic fatty liver disease and chronic vascular complications of diabetes mellitus. **2018**, 14, 99-114		170
87	Hepatoprotective effect of tempol on oxidative toxic stress in STZ-induced diabetic rats. **2018**, 37, 82-86		9
86	NAFLD/NASH in patients with type 2 diabetes and related treatment options. **2018**, 41, 509-521		32
85	Future Perspectives on GLP-1 Receptor Agonists and GLP-1/glucagon Receptor Co-agonists in the Treatment of NAFLD. **2018**, 9, 649		43
84	Kombiglyze (metformin and saxagliptin)-induced hepatotoxicity in a patient with non-alcoholic fatty liver disease. **2018**, 2, 242-245		4
83	Alterations in the gene expression of drug and arachidonic acid-metabolizing Cyp450 in the livers of controlled and uncontrolled insulin-dependent diabetic mice. *Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy*, **2018**, 11, 483-492	3.4	12
82	Integrated analysis of the gene expression profile and DNA methylation profile of obese patients with type 2 diabetes. **2018**, 17, 7636-7644		10
81	Oleander Stem and Root Standardized Extracts Mitigate Acute Hyperglycaemia by Limiting Systemic Oxidative Stress Response in Diabetic Mice. **2019**, 2019, 7865359		3
80	Liver Function and Risk of Type 2 Diabetes: Bidirectional Mendelian Randomization Study. **2019**, 68, 1681-1691		136

79	Sonographic Features of the Liver Among Females with Type 2 Diabetes. **2019**, 35, 189-197	
78	Protective Effect of the Hexanic Extract of Inflorescences In Vitro, in Yeast, and in Streptozotocin-Induced Diabetic Male Rats. **2019**, 8,	8
77	Extra-hepatic manifestations and complications of nonalcoholic fatty liver disease. **2019**, 11, 2171-2192	18
76	Hepatoprotective Effects of a Ruthenium(II) Schiff Base Complex in Rats with Diet-Induced Prediabetes. **2019**, 91, 66-72	2
75	Type 2 Diabetes Prevention Diet and Hepatocellular Carcinoma Risk in US Men and Women. **2019**, 114, 1870-1877	12
74	Generic chemoprevention of hepatocellular carcinoma. **2019**, 1440, 23-35	10
73	An untargeted metabolomics approach reveals further insights of Lycium barbarum polysaccharides in high fat diet and streptozotocin-induced diabetic rats. **2019**, 116, 20-29	22
72	Recovery of metabolic impairment in patients who cleared chronic hepatitis C infection after direct-acting antiviral therapy. **2019**, 53, 559-563	6
71	Food Insecurity May Be an Independent Risk Factor Associated with Nonalcoholic Fatty Liver Disease among Low-Income Adults in the United States. **2020**, 150, 91-98	21
70	Effects of insoluble and soluble fibers isolated from barley on blood glucose, serum lipids, liver function and caecal short-chain fatty acids in type 2 diabetic and normal rats. **2020**, 135, 110937	27
69	NLRP3 inhibitor glibenclamide attenuates high-fat diet and streptozotocin-induced non-alcoholic fatty liver disease in rat: studies on oxidative stress, inflammation, DNA damage and insulin signalling pathway. **2020**, 393, 705-716	13
68	Systematic Transcriptome and Regulatory Network Analyses Reveal the Hypoglycemic Mechanism of Dendrobium fimbriatum. **2020**, 19, 1-14	4
67	Hepatitis B virus infection and the risk of liver disease progression in type 2 diabetic patients with potential nonalcoholic fatty liver disease: a retrospective, observational, cohort study in the United Kingdom Clinical Practice Research Datalink. **2020**, 32, 101-109	1
66	Sublingual microvasculature in diabetic patients. **2020**, 129, 103971	10
65	Cigarette Smoking Increased Risk of Overall Mortality in Patients With Non-alcoholic Fatty Liver Disease: A Nationwide Population-Based Cohort Study. **2020**, 7, 604919	7
64	Sexual Dimorphism of NAFLD in Adults. Focus on Clinical Aspects and Implications for Practice and Translational Research. **2020**, 9,	45
63	Mortality trends of liver cancer among patients with type 2 diabetes at the global and national level. **2020**, 34, 107612	2
62	Protective role of taurine and structurally related compounds against diabetes-induced oxidative stress. **2020**, 351-359	

61	Newly identified peptide hormone inhibits intestinal fat absorption and improves NAFLD through its receptor GPRC6A. **2020**, 73, 383-393		12
60	Treat liver to beat diabetes. **2020**, 144, 110034		1
59	Epidemiology: Pathogenesis, and Diagnostic Strategy of Diabetic Liver Disease in Japan. *International Journal of Molecular Sciences*, **2020**, 21,	6.3	15
58	Does adipose tissue inflammation drive the development of non-alcoholic fatty liver disease in obesity?. **2020**, 44, 394-402		17
57	17□estradiol ameliorates lipotoxicity-induced hepatic mitochondrial oxidative stress and insulin resistance. **2020**, 150, 148-160		17
56	Shorea roxburghii Leaf Extract Ameliorates Hyperglycemia Induced Abnormalities in High Fat/Fructose and Streptozotocin Induced Diabetic Rats. **2020**, 17, e1900661		7
55	Diabetes and liver cancer risk: A stronger effect in Whites than Blacks?. **2021**, 35, 107816		0
54	Peretinoin, an Acyclic Retinoid, for the Secondary Prevention of Hepatocellular Carcinoma. **2021**, 26,		0
53	Effect of gamma conglutin treatment on JNK1 gene expression and protein activation in a rat model of type 2 diabetes. **2021**, 59, 374-380		2
52	Parathyroid hormone-related protein prevents high-fat-diet-induced obesity, hepatic steatosis and insulin resistance in mice. **2021**,		0
51	Empagliflozin Improves Liver Steatosis and Fibrosis in Patients with Non-Alcoholic Fatty Liver Disease and Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial. **2021**, 12, 843-861		18
50	Fluorophore-Dapagliflozin Dyad for Detecting Diabetic Liver/Kidney Damages via Fluorescent Imaging and Treating Diabetes via Inhibiting SGLT2. *Analytical Chemistry*, **2021**, 93, 4647-4656	7.8	3
49	Prolonged □adrenergic agonist treatment improves glucose homeostasis in diet-induced obese UCP1 mice. *American Journal of Physiology - Endocrinology and Metabolism*, **2021**, 320, E619-E628	6	1
48	Hepatic steatosis and hepatic iron overload modify the association of iron markers with glucose metabolism disorders and metabolic syndrome. *Liver International*, **2021**, 41, 1841-1852	7.9	1
47	Impact of HCV infection and ethnicity on incident type 2 diabetes: findings from a large population-based cohort in British Columbia. *BMJ Open Diabetes Research and Care*, **2021**, 9,	4.5	2
46	Transcriptomic changes in peripheral blood mononuclear cells with weight loss: systematic literature review and primary data synthesis. *Genes and Nutrition*, **2021**, 16, 12	4.3	2
45	Network Pharmacology-Based Analysis and Experimental Exploration of Antidiabetic Mechanisms of Gegen Qinlian Decoction. *Frontiers in Pharmacology*, **2021**, 12, 649606	5.6	3
44	Triglyceride glucose (TyG) index and the progression of liver fibrosis: A cross-sectional study. *Clinical Nutrition ESPEN*, **2021**, 44, 483-487	1.3	2

43	Sex-specific expression mechanism of hepatic estrogen inactivating enzyme and transporters in diabetic women. *Biochemical Pharmacology*, **2021**, 190, 114662	6	1
42	Multifactorial Basis and Therapeutic Strategies in Metabolism-Related Diseases. *Nutrients*, **2021**, 13,	6.7	5
41	The interplay between metabolic dysregulations and non-alcoholic fatty liver disease in women after menopause. *Maturitas*, **2021**, 151, 22-30	5	3
40	Discovery and development of CPL207280 as new GPR40/FFA1 agonist. *European Journal of Medicinal Chemistry*, **2021**, 226, 113810	6.8	1
39	Combination of cafeteria diet with intraperitoneally streptozotocin in rats. A type-2 diabetes model. *Acta Cirurgica Brasileira*, **2021**, 36, e360702	1.6	
38	Non-alcoholic Fatty Liver Disease and Diabetes Mellitus. *Advances in Experimental Medicine and Biology*, **2021**, 1307, 417-440	3.6	3
37	Diabetes upregulates the expression of HSP90 and downregulates HSP70 in the liver of diabetic rats. *Comparative Clinical Pathology*, **2019**, 28, 473-478	0.9	4
36	Antidiabetic agents in patients with hepatic impairment. *World Journal of Meta-analysis*, **2019**, 7, 380-388	0.5	3
35	Bidirectional association between nonalcoholic fatty liver disease and type 2 diabetes in Chinese population: Evidence from the Dongfeng-Tongji cohort study. *PLoS ONE*, **2017**, 12, e0174291	3.7	36
34	Serum zinc level and hepatic fibrosis in patients with nonalcoholic fatty liver disease. *PLoS ONE*, **2020**, 15, e0240195	3.7	3
33	Overexpression of Hepassocin in Diabetic Patients with Nonalcoholic Fatty Liver Disease May Facilitate Increased Hepatic Lipid Accumulation. *Endocrine, Metabolic and Immune Disorders - Drug Targets*, **2019**, 19, 185-188	2.2	14
32	Non-alcoholic fatty liver disease and obesity: biochemical, metabolic and clinical presentations. *World Journal of Gastroenterology*, **2014**, 20, 9330-7	5.6	223
31	Alimentary regimen in non-alcoholic fatty liver disease: Mediterranean diet. *World Journal of Gastroenterology*, **2014**, 20, 16831-40	5.6	77
30	Fatty liver disease: Disparate predictive ability for cardiometabolic risk and all-cause mortality. *World Journal of Gastroenterology*, **2015**, 21, 13555-65	5.6	7
29	Severity of Nonalcoholic Fatty Liver Disease in Type 2 Diabetes Mellitus: Relationship between Nongenetic Factors and PNPLA3/HSD17B13 Polymorphisms. *Diabetes and Metabolism Journal*, **2019**, 43, 700-710	5	10
28	Weitere Diabetesformen. **2014**, 203-212		
27	Lipotoxicity Observed at the Early Phase of Obesity in Cats Fed on High-fat Diet. *Asian Journal of Animal and Veterinary Advances*, **2014**, 9, 134-143	0.1	2
26	Bauhinia vahlii and antioxidant potential in diabetes. **2020**, 195-202		

[-]

25	Theophylline Extracted from Fu Brick Tea Affects the Metabolism Of Preadipocytes And Body Fat in Mice as a Pancreatic Lipase Inhibitor. *SSRN Electronic Journal*,	1	
24	The Effect of Stem Cell Transplantation Therapy for Post Viral Chronic Liver Cell Failure on Associated Type II Diabetes Mellitus: A Pilot Study. *Endocrine, Metabolic and Immune Disorders - Drug Targets*, **2020**, 20, 903-916	2.2	5
23	Effects of statins on the risk of hepatocellular carcinoma. *Gastroenterology and Hepatology*, **2014**, 10, 417-26	0.7	15
22	[Parathyroid hormone-related protein aggravates nonalcoholic fatty liver disease induced by methionine choline-deficient diet in mice]. *Nan Fang Yi Ke Da Xue Xue Bao = Journal of Southern Medical University*, **2021**, 41, 1037-1043	0.5	
21	Association Between Aspartate Aminotransferase to Alanine Aminotransferase Ratio and Incidence of Type 2 Diabetes Mellitus in the Japanese Population: A Secondary Analysis of a Retrospective Cohort Study. *Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy*, **2021**, 14, 4483-4495	3.4	1
20	Long-term oral administration of an HNF4□agonist prevents weight gain and hepatic steatosis by promoting increased mitochondrial mass and function.. *Cell Death and Disease*, **2022**, 13, 89	9.8	0
19	Theophylline Extracted from Fu Brick Tea Affects the Metabolism of Preadipocytes and Body Fat in Mice as a Pancreatic Lipase Inhibitor.. *International Journal of Molecular Sciences*, **2022**, 23,	6.3	0
18	Liver steatosis, cardiac and renal fibrosis, and hypertension in overweight rats: Angiotensin-(3-4)-sensitive hepatocardiorenal syndrome.. *Metabolism Open*, **2022**, 14, 100176	2.8	0
17	Association of Two Indices of Insulin Resistance Marker with Abnormal Liver Function Tests: A Cross-Sectional Population Study in Taiwanese Adults.. *Medicina (Lithuania)*, **2021**, 58,	3.1	0
16	N-Doped Carbon Nanorods from Biomass as a Potential Antidiabetic Nanomedicine.. *ACS Biomaterials Science and Engineering*, **2022**,	5.5	1
15	In Vitro and In Ovo Evaluation of the Potential Hepatoprotective Effect of Metformin. *Medicina (Lithuania)*, **2022**, 58, 705	3.1	0
14	Paying the Iron Price: Liver Iron Homeostasis and Metabolic Disease. 3641-3663		0
13	Chinese Herbal Medicine for Type 2 Diabetes Mellitus With Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis. *Frontiers in Pharmacology*, 13,	5.6	1
12	Nonalcoholic Fatty Liver Disease and Altered Neuropsychological Functions in Patients with Subcortical Vascular Dementia. *Journal of Personalized Medicine*, **2022**, 12, 1106	3.6	0
11	Laurolitsine ameliorates type 2 diabetes by regulating the hepatic LKB1-AMPK pathway and gut microbiota. **2022**, 106, 154423		0
10	Comparing the long non-coding RNA expression profiles of skeletal muscle and kidney tissues from patients with diabetes. **2022**, 17, e0274794		0
9	Developmental exposure to indoor flame retardants and hypothalamic molecular signatures: Sex-dependent reprogramming of lipid homeostasis. 13,		0
8	Management of metabolic-associated fatty liver disease: The diabetology perspective. 29, 126-143		0

7	Effect of Oleanolic acid administration on hepatic AMPK, SIRT-1, IL-6 and NF-Β levels in experimental diabetes.	0
6	Elevated alanine transaminase is nonlinearly associated with in-hospital death in ICU-admitted diabetic ketoacidosis patients. **2023**, 197, 110555	0
5	Resveratrol Mitigates Diabetic Testicular Dysfunction, Endocrine Deficits, and Insulin Resistance via Suppression of Sperm-Endocrine Aberrations and Oxidative Inflammation in Rats. **2023**, 2023, 1-10	0
4	mir-98-5p regulates gluconeogenesis and lipogenesis by targeting PPP1R15B in hepatocytes.	0
3	Combinational administration of mesenchymal stem cell-derived exosomes and metformin reduces inflammatory responses in an in vitro model of insulin resistance in HepG2 cells. **2023**, e15489	0
2	Selective aryl hydrocarbon receptor modulators can act as antidepressants in obese female mice. **2023**,	0
1	Assessing the hepatoprotective effects of hesperidin on liver-associated disorders in albino rats with experimentally induced obesity and type II diabetes: A histological and biochemical study. **2023**, 9, e16031	0